|
Epstein-Barr Virus Infections
|
0.040 |
Biomarker
|
group |
BEFREE |
Humans with serologic evidence of Epstein-Barr virus infection had serum antibodies to gp110 and peripheral blood T cells that recognized peptides from gp110 and HLA-Dw4 encompassing the QKRAA determinant.
|
2472638 |
1989 |
|
Rheumatoid Arthritis
|
0.030 |
Biomarker
|
disease |
BEFREE |
An analysis of protein and DNA databases revealed that the Epstein-Barr virus glycoprotein gp110, which is encoded by the BALF4 open reading frame, contains the sequence QKRAAQRAA, which is highly homologous to the rheumatoid arthritis susceptibility determinant.
|
2472638 |
1989 |
|
HIV Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
Although knowledge has accumulated about GP110-CD4 interaction, viral penetration into human CD4+ lymphocytes remains unclear, in spite of the fact that all studies on HIV infection were performed on cell-transformed lineages, or on human polyclonal CD4+ cells.
|
2121340 |
1990 |
|
Epstein-Barr Virus Infections
|
0.040 |
Biomarker
|
group |
BEFREE |
To investigate whether gp110, like gB, is essential for EBV infection, a selectable marker was inserted within the gp110 reading frame, BALF4, and the resulting null mutant EBV stain, B95-110HYG, was recovered in lymphoblastoid cell lines (LCLs).
|
8627735 |
1996 |
|
Herpes Simplex Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
The Epstein-Barr virus (EBV) glycoprotein gp110 has substantial amino acid homology to gB of herpes simplex virus but localizes differently within infected cells and is essentially undetectable in virions.
|
8627735 |
1996 |
|
Multiple Sclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Plasma from 16 patients with MS, eight with OND and 72 healthy donors were tested for antibodies by ELISA to HHV-6 early (p41/38) and late (gp110) proteins.
|
9987758 |
1998 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Northern blot analysis of human breast cancer cell lines revealed 3- to 5-fold elevated ARM-1 mRNA levels in metastatic as compared to non-metastatic cells.
|
10919708 |
1999 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Northern blot analysis of human breast cancer cell lines revealed 3- to 5-fold elevated ARM-1 mRNA levels in metastatic as compared to non-metastatic cells.
|
10919708 |
1999 |
|
Epstein-Barr Virus Infections
|
0.040 |
Biomarker
|
group |
BEFREE |
In addition, gp110(high) viruses infected the carcinoma cell line HeLa and the T cell lymphoma cell line Molt-4, both previously thought to be refractory to EBV infection.
|
12409611 |
2002 |
|
T-Cell Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, gp110(high) viruses infected the carcinoma cell line HeLa and the T cell lymphoma cell line Molt-4, both previously thought to be refractory to EBV infection.
|
12409611 |
2002 |
|
Epstein-Barr Virus Infections
|
0.040 |
Biomarker
|
group |
BEFREE |
HLA-DRB1*0404, an RA predisposing allele, is associated with low frequencies of T cells specific for EBV gp110, a replicative phase glycoprotein critical for the control of EBV infection.
|
15288002 |
2004 |
|
Rheumatoid Arthritis
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
HLA-DRB1*0404, an RA predisposing allele, is associated with low frequencies of T cells specific for EBV gp110, a replicative phase glycoprotein critical for the control of EBV infection.
|
15288002 |
2004 |
|
Rheumatoid Arthritis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Cell-mediated responses to EBV replicative cycle proteins and to gp110 have been documented in joint fluid from RA patients.
|
17625943 |
2007 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Of the 19 candidate genes in this subset, ADRM1 overexpression was the most highly correlated with amplification, was amplified in a higher percentage of tumors than ZNF217 and TPD54, and was significantly upregulated with respect to stage, recurrence and metastasis.
|
18615678 |
2008 |
|
Malignant neoplasm of ovary
|
0.030 |
Biomarker
|
disease |
BEFREE |
Functional analysis is now warranted to determine whether ADRM1 is a target for early screening and/or therapy for ovarian cancer.
|
18615678 |
2008 |
|
Carcinoma, Ovarian Epithelial
|
0.030 |
Biomarker
|
disease |
BEFREE |
Functional analysis is now warranted to determine whether ADRM1 is a target for early screening and/or therapy for ovarian cancer.
|
18615678 |
2008 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Of the 19 candidate genes in this subset, ADRM1 overexpression was the most highly correlated with amplification, was amplified in a higher percentage of tumors than ZNF217 and TPD54, and was significantly upregulated with respect to stage, recurrence and metastasis.
|
18615678 |
2008 |
|
ovarian neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
Functional analysis is now warranted to determine whether ADRM1 is a target for early screening and/or therapy for ovarian cancer.
|
18615678 |
2008 |
|
ovarian neoplasm
|
0.020 |
AlteredExpression
|
disease |
LHGDN |
Functional analysis is now warranted to determine whether ADRM1 is a target for early screening and/or therapy for ovarian cancer.
|
18615678 |
2008 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Collectively, these data suggested that Adrm1 is potentially oncogenic and may play an important role in colon tumorigenesis.
|
19148532 |
2009 |
|
Colorectal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Regiment with combined application of Adrm1 RNA interference and chemotherapy may emerge as a novel therapeutic strategy for Adrm1 overexpressed colorectal cancer.
|
19148532 |
2009 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Adrm1 mRNA was overexpressed in 46.2% (18/39) colorectal cancer tissues compared to their matched normal mucosa and significantly correlated with lymph node metastasis of colorectal cancer (P=0.037).
|
19148532 |
2009 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Regiment with combined application of Adrm1 RNA interference and chemotherapy may emerge as a novel therapeutic strategy for Adrm1 overexpressed colorectal cancer.
|
19148532 |
2009 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Further research is necessary to determine whether targeting knockdown of ADRM1 in 20q13-amplified ovarian cancers results in growth inhibition and tumor suppression via downstream targets GIPC1 and RECK.
|
21432940 |
2011 |
|
Malignant neoplasm of ovary
|
0.030 |
Biomarker
|
disease |
BEFREE |
Further research is necessary to determine whether targeting knockdown of ADRM1 in 20q13-amplified ovarian cancers results in growth inhibition and tumor suppression via downstream targets GIPC1 and RECK.
|
21432940 |
2011 |